References
- Devita V. T., Hubbard S. M., Young R. C., Longo D. L. The role of chemotherapy in diffuse aggressive lymphoma. Semin. Hematol. 1988; 25(2)2–10
- Cabanillas F., Hagemeister F. B., Bodey G. P., Freirich E. J. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
- Velasquez W. S., Swan F., Redman J., et al. Combination of etoposide, high dose ARA-C and solumedrol with or without platinol in relapsing or resistant lymphoma. Proceedings of ASCO 1989; 8: 256
- Petersen F. B., Appelbaum F. R., Hill R., et al. Autologous marrow transplant for malignant lymphoma: a report of 101 cases from Seattle. J. Clin. Oncol. 1990; 8: 638–647
- Philip T., Armitage J., Spitzer G., et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade and high grade non-Hodgkin lymphoma. New Engl. J. Med. 1987; 316: 1493–1498
- Takvorian T., Canellos G., Ritz J., et al. Prolonged disease free survival after autologous bone marrow transplantation in patients with non Hodgkin's lymphoma with a poor prognosis. New. Engl. J. Med. 1987; 316: 1499–1505
- Meloni G., De Fabritiis P., Papa G., et al. Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients with acute myeloblastic leukemia in first relapse. Leuk. Res. 1985; 9: 407
- Philip T., Chauvin F., Armitage J., et al. Parma International Protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77(7)1587–1592
- Tutschka P. J., Copelan E. A., Klein J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382
- Cabanillas F., Hagemeister F. B., McLaughlin P., et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J. Clin. Oncol 1987; 5(3)407–412
- Velasquez W. S., Cabanillas F., Salvadore P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose ARA-C and dexamethasone (DHAP). Blood 1988; 71: 117
- Goldstone A. H., McMillan A. K., Chopra R. High dose therapy for the treatment of non Hodgkin's lymphoma. High dose cancer therapy: Pharmacology, Hematopoietins, stem cells, J. O. Armitage, K. H. Antman. Williams and Wilkins, Baltimore 1992; 662–676
- Guglielmi C., Chauvin F., Hagenbee K. A., et al (1993) The Parma International randomized prospective study in relapsed non Hodgkin lymphoma: second interim analysis of 172 patients and update. Proceedings of the Fifth International Conference on Malignant Lymphoma, Lugano, 1993, Abs. 92
- Haioun C., Lepage E., Gisselbrecht G., et al. Autologous bone marrow transplantation versus sequential chemotherapy in first complete remission aggressive non Hodgkin's lymphoma. Proceedings of the Fifth International Conference on Malygnant Lymphoma, LuganoSwitzerland, 1993, 41, Abstr. 48
- Tura S., Zinzani P. L., Mazza P., et al. ABMT vs DHAP in residual disease following third generation regimens for aggressive non Hodgkin's lymphoma. Blood 1992; 80(1)157, (abstr. 619)
- Verdonck L. F., Van Putten W. L. J., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995; 332: 1045–1051
- Gianni A. M., Bregni M., Siena S., et al (1994) 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. Proceedings of conferenza CNR P.F. ACRO “La Ricerca Oncolog-ica in Italia”, Roma, June, 9–101994, 459, edited by CNR-Roma